Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen Idec 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Biogen Idec 1Q

Growth was driven by Tysabri sales up 44% to $165 million, Rituxan sales through the company's partnership with Genentech were up 13% to $279 million, and Avonex sales were up 4% to $555 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 1Q

1Q Revenues: $1.0 billion (+10%)

1Q Earnings: $244 million (+50%)

Comments: Growth was driven by Tysabri sales up 44% to $165 million, Rituxan sales through the company’s partnership with Genentech were up 13% to $279 million, and Avonex sales were up 4% to $555 million. Global sales of Tysabri, co-promoted with Elan Corp., were $227 million, of which $116 million was in the U.S. and $111 million ROW.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters